Biomarkers of Peripheral Arterial Disease

Journal of the American College of Cardiology

Volumn 55, Issue 19, 2010, Pages 2017-2023

  Cooke, John P ^a   Wilson, Andrew M ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

2 microglobulin; ankle brachial index; C reactive peptide; cystatin C; peripheral arterial disease

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CHEMOKINE; CYSTATIN C; CYTOKINE; IMMUNOGLOBULIN; PLASMA PROTEIN; PROTEIN DERIVATIVE; PROTEOME; TRANSCRIPTOME;

ANGIOGRAPHY; ANKLE BRACHIAL INDEX; BLOOD ANALYSIS; CORONARY ARTERY DISEASE; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE MARKER; DOPPLER FLOWMETRY; GENOME; HUMAN; METABOLOME; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; HUMANS; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; RISK FACTORS;

EID: 77951685239     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.08.090     Document Type: Review

References (89)

1. Brevetti G., Oliva G., Silvestro A., Scopacasa F., and Chiariello M. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis 175 (2004) 131-138
2. Criqui M.H., Vargas V., Denenberg J.O., et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation 112 (2005) 2703-2707
3. Hayoz D., Bounameaux H., and Canova C.R. Swiss Atherothrombosis Survey: a field report on the occurrence of symptomatic and asymptomatic peripheral arterial disease. J Intern Med 258 (2005) 238-243
4. Hasimu B., Li J., Nakayama T., et al. Ankle brachial index as a marker of atherosclerosis in Chinese patients with high cardiovascular risk. Hypertens Res 29 (2006) 23-28
5. Criqui M.H., Fronek A., Barrett-Connor E., Klauber M.R., Gabriel S., and Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 71 (1985) 510-515
6. Criqui M.H. Peripheral arterial disease-epidemiological aspects. Vasc Med 6 (2001) 3-7
7. McDermott M.M., Liu K., Greenland P., et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 292 (2004) 453-461
8. Criqui M.H., and Denenberg J.O. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med 3 (1998) 241-245
9. Newman A.B., Shemanski L., Manolio T.A., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 538-545
10. Newman A.B., Tyrrell K.S., and Kuller L.H. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc 45 (1997) 1472-1478
11. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992) 381-386
12. Gornik H.L., and Creager M.A. Contemporary management of peripheral arterial disease: I. cardiovascular risk-factor modification. Cleve Clin J Med 73 suppl 4 (2006) S30-S37
13. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324
14. Hirsch A.T., Murphy T.P., Lovell M.B., et al. Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation 116 (2007) 2086-2094
15. Beckman J.A., Jaff M.R., and Creager M.A. The United States preventive services task force recommendation statement on screening for peripheral arterial disease: more harm than benefit?. Circulation 114 (2006) 861-866
16. McDermott M.M., Greenland P., Liu K., et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 286 (2001) 1599-1606
17. Criqui M.H., Fronek A., Klauber M.R., Barrett-Connor E., and Gabriel S. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation 71 (1985) 516-522
18. Leng G.C., and Fowkes F.G. The Edinburgh claudication questionnaire: an improved version of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol 45 (1992) 1101-1109
19. Lijmer J.G., Hunink M.G., van den Dungen J.J., Loonstra J., and Smit A.J. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 22 (1996) 391-398
20. Fowkes F.G. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 17 (1988) 248-254
21. Fowkes F.G., Murray G.D., Butcher I., et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300 (2008) 197-208
22. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113 (2006) e463-e654
23. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 26 (2003) 3333-3341
24. United States Preventive Services Task Force. Recommendation statement: screening for peripheral arterial disease (2005), Agency for Healthcare and Quality, Washington, DC 1-8
25. Leng G.C., Fowkes F.G., Lee A.J., Dunbar J., Housley E., and Ruckley C.V. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 313 (1996) 1440-1444
26. McKenna M., Wolfson S., and Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 87 (1991) 119-128
27. Ouriel K. Peripheral arterial disease. Lancet 358 (2001) 1257-1264
28. Hankey G.J., Norman P.E., and Eikelboom J.W. Medical treatment of peripheral arterial disease. JAMA 295 (2006) 547-553
29. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344 (2001) 1608-1621
30. Daskalopoulou S.S., Daskalopoulos M.E., Liapis C.D., and Mikhailidis D.P. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 12 (2005) 443-452
31. Federman D.G., Ranani D.C., Kirsner R.S., and Bravata D.M. Lipid-lowering therapy in patients with peripheral arterial disease: are guidelines being met?. Mayo Clin Proc 80 (2005) 494-498
32. Hiatt W.R., and Krantz M.J. Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. Vasc Med 11 (2006) 55-60
33. Feringa H.H., van Waning V.H., Bax J.J., et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 47 (2006) 1182-1187
34. Okaa R.K., Umoh E., Szuba A., Giacomini J.C., and Cooke J.P. Suboptimal intensity of risk factor modification in PAD. Vasc Med 10 (2005) 91-96
35. Gerszten R.E., and Wang T.J. The search for new cardiovascular biomarkers. Nature 451 (2008) 949-952
36. Anderson N.L., Polanski M., Pieper R., et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3 (2004) 311-326
37. Granger C.B., Van Eyk J.E., Mockrin S.C., and Anderson N.L. National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation 109 (2004) 1697-1703
38. Muthusamy B., Hanumanthu G., Suresh S., et al. Plasma Proteome Database as a resource for proteomics research. Proteomics 5 (2005) 3531-3536
39. Berhane B.T., Zong C., Liem D.A., et al. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 5 (2005) 3520-3530
40. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
41. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., and Fowkes F.G. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112 (2005) 976-983
42. Murabito J.M., Keyes M.J., Guo C.Y., et al. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: the Framingham Offspring Study. Atherosclerosis 203 (2008) 509-514
43. Mittermayer F., Krzyzanowska K., Exner M., et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 26 (2006) 2536-2540
44. Krzyzanowska K., Mittermayer F., Krugluger W., et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 189 (2006) 236-240
45. Miyazaki H., Matsuoka H., Cooke J.P., et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99 (1999) 1141-1146
46. Boger R.H., Bode-Boger S.M., Thiele W., Junker W., Alexander K., and Frolich J.C. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95 (1997) 2068-2074
47. Brevetti G., Schiano V., and Chiariello M. Cellular adhesion molecules and peripheral arterial disease. Vasc Med 11 (2006) 39-47
48. Kappelmayer J., Nagy Jr. B., Miszti-Blasius K., Hevessy Z., and Setiadi H. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 42 (2004) 475-486
49. Lee A.J., MacGregor A.S., Hau C.M., et al. The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh artery study. Br J Haematol 105 (1999) 648-654
50. Findley C.M., Mitchell R.G., Duscha B.D., Annex B.H., and Kontos C.D. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol 52 (2008) 387-393
51. Yoshitomi Y., Kojima S., Umemoto T., et al. Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J Clin Endocrinol Metab 84 (1999) 2425-2428
52. Tsimikas S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 8 (2006) 55-61
53. Tsimikas S., Kiechl S., Willeit J., et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 47 (2006) 2219-2228
54. Fraley A.E., and Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 17 (2006) 502-509
55. Sutton-Tyrrell K., Evans R.W., Meilahn E., and Alcorn H.G. Lipoprotein(a) and peripheral atherosclerosis in older adults. Atherosclerosis 122 (1996) 11-19
56. Malinow M.R. Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review. Clin Chem 41 (1995) 173-176
57. Loffredo L., Marcoccia A., Pignatelli P., et al. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J 28 (2007) 608-612
58. 2α: a new and independent predictor of peripheral arterial disease. J Vasc Surg 40 (2004) 768-773
59. Seigneur M., Dufourcq P., Conri C., et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res 71 (1993) 423-431
60. Vidula H., Tian L., Liu K., et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med 148 (2008) 85-93
61. Mustonen P., Lepantalo M., and Lassila R. Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis. Arterioscler Thromb Vasc Biol 18 (1998) 244-249
62. Vu J.D., Vu J.B., Pio J.R., et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol 96 (2005) 655-658
63. Vainas T., Stassen F.R., de Graaf R., et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg 42 (2005) 243-251
64. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
65. Aird W.C. Endothelial Cells in Health and Disease (2005), Taylor & Francis, Boca Raton, FL
66. Ho M., Yang E., Matcuk G., et al. Identification of endothelial cell genes by combined database mining and microarray analysis. Physiol Genomics 13 (2003) 249-262
67. Vanhoutte P.M., and Miller V.M. Heterogeneity of endothelium-dependent responses in mammalian blood vessels. J Cardiovasc Pharmacol 7 Suppl 3 (1985) S12-S23
68. Luscher T.F., Cooke J.P., Houston D.S., Neves R.J., and Vanhoutte P.M. Endothelium-dependent relaxations in human arteries. Mayo Clin Proc 62 (1987) 601-606
69. Kunkel E.J., and Butcher E.C. Chemokines and the tissue-specific migration of lymphocytes. Immunity 16 (2002) 1-4
70. Geary R.L., Wong J.M., Rossini A., Schwartz S.M., and Adams L.D. Expression profiling identifies 147 genes contributing to a unique primate neointimal smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 22 (2002) 2010-2016
71. Deng D.X., Tsalenko A., Vailaya A., et al. Differences in vascular bed disease susceptibility reflect differences in gene expression response to atherogenic stimuli. Circ Res 98 (2006) 200-208
72. Carden D.L., and Granger D.N. Pathophysiology of ischaemia-reperfusion injury. J Pathol 190 (2000) 255-266
73. Wilson A.M., Kimura E., Harada R.K., et al. β2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 116 (2007) 1396-1403
74. Snyder N., Nguyen A., Gajula L., et al. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta 381 (2007) 119-123
75. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
76. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639
77. Fung E.T., Wilson A.M., Zhang F., et al. A biomarker panel for peripheral arterial disease. Vasc Med 13 (2008) 217-224
78. 2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med 168 (2008) 200-206
79. McDermott M.M., Guralnik J.M., Corsi A., et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J 150 (2005) 276-281
80. Allison M.A., Criqui M.H., McClelland R.L., et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 48 (2006) 1190-1197
81. Libra M., Signorelli S.S., Bevelacqua Y., et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 59 (2006) 211-215
82. Fiotti N., Giansante C., Ponte E., et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145 (1999) 51-60
83. Danielsson P., Truedsson L., Eriksson K.F., and Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc Med 10 (2005) 191-198
84. Ziegler S., Kudlacek S., Luger A., and Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182 (2005) 175-180
85. DePalma R.G., Hayes V.W., Cafferata H.T., et al. Cytokine signatures in atherosclerotic claudicants. J Surg Res 111 (2003) 215-221
86. Nylaende M., Kroese A., Stranden E., et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 11 (2006) 21-28
87. Hoogeveen R.C., Morrison A., Boerwinkle E., et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities Study. Atherosclerosis 183 (2005) 301-307
88. Girn H.R., Orsi N.M., and Homer-Vanniasinkam S. An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease. Vasc Med 12 (2007) 299-309
89. Tayebjee M.H., Tan K.T., MacFadyen R.J., and Lip G.Y. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J Intern Med 257 (2005) 110-116